British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
CA Lamb, NA Kennedy, T Raine, PA Hendy, PJ Smith… - Gut, 2019 - gut.bmj.com
Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …
Both represent chronic inflammation of the gastrointestinal tract, which displays …
[HTML][HTML] SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD …
SARS-CoV-2 has caused a global health crisis and mass vaccination programmes provide
the best opportunity for controlling transmission and protecting populations. Despite the …
the best opportunity for controlling transmission and protecting populations. Despite the …
Gastric antral vascular ectasia (GAVE): an update on clinical presentation, pathophysiology and treatment
CP Selinger, YS Ang - Digestion, 2008 - karger.com
Gastric antral vascular ectasia (GAVE), though a rare disorder, causes up to 4% of non-
variceal upper GI bleeding. This paper gives an overview of studies examining clinical …
variceal upper GI bleeding. This paper gives an overview of studies examining clinical …
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Background Anti-TNF drugs are effective treatments for the management of Crohn's disease
but treatment failure is common. We aimed to identify clinical and pharmacokinetic factors …
but treatment failure is common. We aimed to identify clinical and pharmacokinetic factors …
[HTML][HTML] HLA-DQA1* 05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease
Background & Aims Anti–tumor necrosis factor (anti-TNF) therapies are the most widely
used biologic drugs for treating immune-mediated diseases, but repeated administration can …
used biologic drugs for treating immune-mediated diseases, but repeated administration can …
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic
The COVID-19 pandemic is putting unprecedented pressures on healthcare systems
globally. Early insights have been made possible by rapid sharing of data from China and …
globally. Early insights have been made possible by rapid sharing of data from China and …
European Crohn's and colitis guidelines on sexuality, fertility, pregnancy, and lactation
J Torres, M Chaparro, M Julsgaard… - Journal of Crohn's …, 2023 - academic.oup.com
2. Methods This document represents the third version of the European Consensus on
reproduction in IBD. The development of this Consensus included the formulation of …
reproduction in IBD. The development of this Consensus included the formulation of …
Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views
CP Selinger, J Eaden, W Selby… - Journal of Crohn's …, 2013 - academic.oup.com
Background: Enabling women with inflammatory bowel diseases (IBD) to have successful
pregnancies requires complex decisions. The study aimed to assess patients' views on IBD …
pregnancies requires complex decisions. The study aimed to assess patients' views on IBD …
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
NA Kennedy, JR Goodhand, C Bewshea, R Nice… - Gut, 2021 - gut.bmj.com
Objective Antitumour necrosis factor (anti-TNF) drugs impair protective immunity following
pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious …
pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious …
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study
BG Feagan, J Panés, M Ferrante, A Kaser… - The Lancet …, 2018 - thelancet.com
Background Risankizumab, an anti-interleukin 23 antibody, was superior to placebo in
achieving clinical and endoscopic remission at week 12 in a randomised, phase 2 induction …
achieving clinical and endoscopic remission at week 12 in a randomised, phase 2 induction …